-
Je něco špatně v tomto záznamu ?
Anti-transcription intermediary factor 1-gamma IgG2 isotype is associated with cancer in adult dermatomyositis: an ENMC multinational study
N. Cordel, B. Dechelotte, F. Jouen, JA. Lamb, H. Chinoy, P. New, J. Vencovsky, H. Mann, AS. Galindo-Feria, L. Dani, A. Selva-O'Callaghan, VP. Werth, A. Ravishankar, O. Landon-Cardinal, B. Tressières, O. Boyer
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, práce podpořená grantem
Grantová podpora
MR/N003322/1
Medical Research Council - United Kingdom
NLK
Free Medical Journals
od 1996 do Před 1 rokem
Open Access Digital Library
od 1996-01-01
Medline Complete (EBSCOhost)
od 1999-01-01 do Před 1 rokem
- MeSH
- analýza mediace MeSH
- autoprotilátky MeSH
- biologické markery MeSH
- dermatomyozitida * MeSH
- dospělí MeSH
- imunoglobulin G MeSH
- lidé středního věku MeSH
- lidé MeSH
- nádory * komplikace MeSH
- retrospektivní studie MeSH
- senioři MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- senioři MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
OBJECTIVE: To assess the role of the anti-TIF1γ auto-antibody (aAb) IgG2 isotype as a biomarker of cancer in anti-TIF1γ aAb-positive adult DM. METHODS: International multicentre retrospective study with the following inclusion criteria: (i) diagnosis of DM according to ENMC criteria; (ii) presence of anti-TIF1γ IgG aAb determined using an in-house addressable laser bead immunoassay (ALBIA) from cryopreserved serums sampled at time of DM diagnosis and (iii) available baseline characteristics and follow-up data until the occurrence of cancer and/or a minimum follow-up of 1 year for patients without known cancer at diagnosis. Detection and quantification of anti-TIF1γ IgG2 aAb was done using the in-house ALBIA. In addition, a recent ELISA commercial kit was used for anti-TIF1γ IgG aAb quantification. RESULTS: A total of 132 patients (mean age 55±15 years) of whom 72 (54.5%) had an associated cancer were analysed. The association between the presence of cancer and the presence of anti-TIF1γ IgG2 aAb was statistically significant (P = 0.026), with an OR of 2.26 (95% CI: 1.10, 4.76). Patients with cancer displayed significantly higher anti-TIF1γ IgG2 aAb ALBIA values with a median value of 1.15 AU/ml (IQR: 0.14-9.76) compared with 0.50 AU/ml (IQR: 0.14-1.46) for patients without cancer (P = 0.042). In addition, patients with cancer displayed significantly higher anti-TIF1γ IgG aAb ELISA values with a median value of 127.5 AU/ml (IQR: 81.5-139.6) compared with 93.0 AU/ml (IQR: 54.0-132.9) for patients without cancer (P = 0.004). CONCLUSION: These results suggest considering anti-TIF1γ IgG2 ALBIA and IgG ELISA values as biomarkers of cancer in anti-TIF1 γ aAb-positive adult DM.
Centre d'Investigation Clinique Antilles Guyane INSERM CIC 1424 Pointe à Pitre Guadeloupe
Department of Immunology and Biotherapy Rouen University Hospital Rouen France
Department of Internal Medicine Vall d'Hebron Hospital Universitat Autònoma Barcelona Spain
Department of Medicine University of Montreal Montreal Quebec Canada
Department of Rheumatology 1st Medical Faculty Charles University Praha Czech Republic
Division of Rheumatology Department of Medicine Karolinska Institute Stockholm Solna Sweden
Institute of Rheumatology Na Slupi 4 Praha 2 Czech Republic
ME Gastro Derm Rheuma Karolinska University Hospital Stockholm Sweden
Univ Rouen Normandie FOCIS Center of Excellence PAn'THER Inserm U1234 Rouen France
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23010507
- 003
- CZ-PrNML
- 005
- 20230801132453.0
- 007
- ta
- 008
- 230718s2023 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1093/rheumatology/keac577 $2 doi
- 035 __
- $a (PubMed)36250907
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Cordel, Nadège $u Department of Dermatology and Clinical Immunology, Guadeloupe University Hospital, Pointe-à-Pitre, Guadeloupe $u Univ Rouen Normandie, FOCIS Center of Excellence PAn'THER, Inserm, U1234, Rouen, France $1 https://orcid.org/0000000316798005
- 245 10
- $a Anti-transcription intermediary factor 1-gamma IgG2 isotype is associated with cancer in adult dermatomyositis: an ENMC multinational study / $c N. Cordel, B. Dechelotte, F. Jouen, JA. Lamb, H. Chinoy, P. New, J. Vencovsky, H. Mann, AS. Galindo-Feria, L. Dani, A. Selva-O'Callaghan, VP. Werth, A. Ravishankar, O. Landon-Cardinal, B. Tressières, O. Boyer
- 520 9_
- $a OBJECTIVE: To assess the role of the anti-TIF1γ auto-antibody (aAb) IgG2 isotype as a biomarker of cancer in anti-TIF1γ aAb-positive adult DM. METHODS: International multicentre retrospective study with the following inclusion criteria: (i) diagnosis of DM according to ENMC criteria; (ii) presence of anti-TIF1γ IgG aAb determined using an in-house addressable laser bead immunoassay (ALBIA) from cryopreserved serums sampled at time of DM diagnosis and (iii) available baseline characteristics and follow-up data until the occurrence of cancer and/or a minimum follow-up of 1 year for patients without known cancer at diagnosis. Detection and quantification of anti-TIF1γ IgG2 aAb was done using the in-house ALBIA. In addition, a recent ELISA commercial kit was used for anti-TIF1γ IgG aAb quantification. RESULTS: A total of 132 patients (mean age 55±15 years) of whom 72 (54.5%) had an associated cancer were analysed. The association between the presence of cancer and the presence of anti-TIF1γ IgG2 aAb was statistically significant (P = 0.026), with an OR of 2.26 (95% CI: 1.10, 4.76). Patients with cancer displayed significantly higher anti-TIF1γ IgG2 aAb ALBIA values with a median value of 1.15 AU/ml (IQR: 0.14-9.76) compared with 0.50 AU/ml (IQR: 0.14-1.46) for patients without cancer (P = 0.042). In addition, patients with cancer displayed significantly higher anti-TIF1γ IgG aAb ELISA values with a median value of 127.5 AU/ml (IQR: 81.5-139.6) compared with 93.0 AU/ml (IQR: 54.0-132.9) for patients without cancer (P = 0.004). CONCLUSION: These results suggest considering anti-TIF1γ IgG2 ALBIA and IgG ELISA values as biomarkers of cancer in anti-TIF1 γ aAb-positive adult DM.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a senioři $7 D000368
- 650 12
- $a dermatomyozitida $7 D003882
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a imunoglobulin G $7 D007074
- 650 _2
- $a analýza mediace $7 D000081983
- 650 _2
- $a autoprotilátky $7 D001323
- 650 12
- $a nádory $x komplikace $7 D009369
- 650 _2
- $a biologické markery $7 D015415
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Dechelotte, Benoît $u Univ Rouen Normandie, FOCIS Center of Excellence PAn'THER, Inserm, U1234, Rouen, France $u Department of Immunology and Biotherapy, Rouen University Hospital, Rouen, France
- 700 1_
- $a Jouen, Fabienne $u Univ Rouen Normandie, FOCIS Center of Excellence PAn'THER, Inserm, U1234, Rouen, France $u Department of Immunology and Biotherapy, Rouen University Hospital, Rouen, France
- 700 1_
- $a Lamb, Janine A $u Epidemiology and Public Health Group, School of Health Sciences, University of Manchester, Manchester, UK
- 700 1_
- $a Chinoy, Hector $u National Institute for Health Research Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, The University of Manchester, Manchester, UK $u Department of Rheumatology, Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Manchester Academic Health Science Centre, Salford, UK $1 https://orcid.org/0000000164921288
- 700 1_
- $a New, Paul $u Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, University of Manchester, Manchester, UK
- 700 1_
- $a Vencovsky, Jiri $u Institute of Rheumatology, Na Slupi 4, Praha 2, Czech Republic $u Department of Rheumatology, 1st Medical Faculty, Charles University, Praha, Czech Republic
- 700 1_
- $a Mann, Herman $u Institute of Rheumatology, Na Slupi 4, Praha 2, Czech Republic $u Department of Rheumatology, 1st Medical Faculty, Charles University, Praha, Czech Republic
- 700 1_
- $a Galindo-Feria, Angeles S $u Division of Rheumatology, Department of Medicine, Karolinska Institute Stockholm, Solna, Sweden $u ME Gastro, Derm, Rheuma, Karolinska University Hospital, Stockholm, Sweden $1 https://orcid.org/000000017095211X
- 700 1_
- $a Dani, Lara $u Division of Rheumatology, Department of Medicine, Karolinska Institute Stockholm, Solna, Sweden $u ME Gastro, Derm, Rheuma, Karolinska University Hospital, Stockholm, Sweden
- 700 1_
- $a Selva-O'Callaghan, Albert $u Department of Internal Medicine, Vall d'Hebron Hospital, Universitat Autònoma Barcelona, Spain $1 https://orcid.org/0000000328239761
- 700 1_
- $a Werth, Victoria P $u Department of Dermatology, University of Pennsylvania and Corporal Michael L. Creszenc (PHL) VAMC, Philadelphia, PA, USA
- 700 1_
- $a Ravishankar, Adarsh $u Department of Dermatology, University of Pennsylvania and Corporal Michael L. Creszenc (PHL) VAMC, Philadelphia, PA, USA
- 700 1_
- $a Landon-Cardinal, Océane $u Department of Medicine, University of Montreal, Montreal, Quebec, Canada $u Division of Rheumatology and Research Center, Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Canada
- 700 1_
- $a Tressières, Benoit $u Centre d'Investigation Clinique Antilles Guyane, INSERM CIC 1424, Pointe-à-Pitre, Guadeloupe
- 700 1_
- $a Boyer, Olivier $u Univ Rouen Normandie, FOCIS Center of Excellence PAn'THER, Inserm, U1234, Rouen, France $u Department of Immunology and Biotherapy, Rouen University Hospital, Rouen, France
- 773 0_
- $w MED00011379 $t Rheumatology (Oxford, England) $x 1462-0332 $g Roč. 62, č. 4 (2023), s. 1711-1715
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36250907 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230718 $b ABA008
- 991 __
- $a 20230801132450 $b ABA008
- 999 __
- $a ok $b bmc $g 1963122 $s 1196772
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 62 $c 4 $d 1711-1715 $e 2023Apr03 $i 1462-0332 $m Rheumatology $n Rheumatology (Oxford) $x MED00011379
- GRA __
- $a MR/N003322/1 $p Medical Research Council $2 United Kingdom
- LZP __
- $a Pubmed-20230718
